Olanzapine- and Clozapine-induced Stuttering

 

 Buy Article Permissions and Reprints

Drug-induced stuttering has been described in association with several drugs, in particular antidepressants and low-potency neuroleptics. Here we describe a case series of stuttering induced by the atypical neuroleptics olanzapine and clozapine.

Patients receiving neuroleptic treatment were carefully screened for stuttering as a possible side effect. We have studied all patients in the outpatient department (800 per year) as well as most inpatients (1300 per year) within 3 years.

Seven cases of drug-induced stuttering were observed. Six patients suffered from stuttering in association with olanzapine treatment, and one received clozapine. Stuttering arose on average 2-21 days after initiation of treatment and ceased 2-5 days after discontinuation. Most patients suffered from additional diseases, such as brain pathology due to cortical atrophy or celiac disease, or received concomitant medication (i. e. intrathecal morphine pump).

Our case series suggests that the atypical neuroleptic olanzapine can induce stuttering in the absence of a history of stuttering without accompanying akathisia or general decline of function. It appears that preexisting brain pathology or concomitant antidepressant medication might predispose some patients to this side effect.

References

• 1 Bhana N, Foster R H, Olney R, Plosker G L. Olanzapine: an updated review of its use in the management of schizophrenia.  Drugs. 2001;  61 111-161
  PubMedGoogle Scholar
• 2 Brady J P. Drug-induced stuttering: a review of the literature.  J Clin Psychopharmacol. 1998;  18 50-54
  CrossrefPubMedGoogle Scholar
• 3 Burns D, Brady J P, Kuruvilla K. The acute effect of haloperidol and apomorphine on the severity of stuttering.  Biol Psychiat. 1978;  13 255-264
  PubMedGoogle Scholar
• 4 Burns M J. The pharmacology and toxicology of atypical antipsychotic agents.  J Toxicol Clin Toxicol. 2001;  39 1-14
  CrossrefPubMedGoogle Scholar
• 5 Ebeling T A, Compton A D, Albright D W. Clozapine-induced stuttering.  Am J Psychiat. 1997;  154 1473
  PubMedGoogle Scholar
• 6 Eschweiler G W, Bartels M, Langle G, Wild B, Gaertner I, Nickola M. Heart-rate variability (HRV) in the ECG trace of routine EEGs: fast monitoring for the anticholinergic effects of clozapine and olanzapine?.  Pharmacopsychiatry. 2002;  35(3) 96-100
  Article in Thieme ConnectPubMedGoogle Scholar
• 7 Friedman E H. Fluoxetine and stuttering.  J Clin Psychiat. 1990;  51 310-311
  PubMedGoogle Scholar
• 8 Gaile S, Noviasky J A. Speech disturbance and marked decrease in function seen in several older patients on olanzapine.  J Am Geriat Soc. 1998;  46 1330-1331
  PubMedGoogle Scholar
• 9 Horacek J. Novel antipsychotics and extrapyramidal side effects. Theory and reality.  Pharmacopsychiatry. 2000;  33 24-42
  PubMedGoogle Scholar
• 10 Kent R D. Research on speech motor control and its disorders: a review and prospective.  J Commun Disord. 2000;  33 391-427
  CrossrefPubMedGoogle Scholar
• 11 Lee H J, Lee H S, Kim L, Lee M S, Suh K Y, Kwak D I. A case of risperidone-induced stuttering.  J Clin Psychopharmacol. 2001;  21 115-116
  CrossrefPubMedGoogle Scholar
• 12 Maguire G A, Riley G D, Franklin D L, Gottschalk L A. Risperidone for the treatment of stuttering.  J Clin Psychopharmacol. 2000;  20 479-482
  CrossrefPubMedGoogle Scholar
• 13 Marsalek M. Tardive drug-induced extrapyramidal syndromes. Pharmacopsychiatry 2000: 14-33
  Google Scholar
• 14 Menkes D B, Ungvari G S. Adult-onset stuttering as a presenting feature of schizophrenia: restoration of fluency with trifluoperazine.  J Nerv Ment Dis. 1993;  181 64-65
  PubMedGoogle Scholar
• 15 Thomas P, Lalaux N, Vaiva G, Goudemand M. Dose-dependent stuttering and dystonia in a patient taking clozapine.  Am J Psychiat. 1994;  151 1096
  PubMedGoogle Scholar

Dr. K.-J. Bär

Klinik für Psychiatrie

Philosophenweg 3

07743 Jena

Germany

Phone: +49-3641-935282

Fax: +49-3641-935280

Email: Karl-Juergen.Baer@med.uni-jena.de